LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it intends to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its shareholders. The Company currently expects to file a registration statement in connection with the proposed rights offering. Subject to and following the SEC declaring the registration statement effective, the Company intends to distribute...

– Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven patients in the trial –  – Marks the latest in a series of regulatory successes in this indication, following FDA’s recognition of Alpha DaRT’s potential through its Breakthrough Device Designation for recurrent glioblastoma (GBM) and Alpha Tau’s selection for the FDA’s prestigious Total Product Life Cycle (TPLC) Advisory Program (TAP) – – With approximately 14,000 Americans newly diagnosed with glioblastoma each year and median survival after recurrence typically measured in months, Alpha DaRT® represents a potentially transformative new treatment option for patients with highly limited alternatives – –...

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company, today announced that its Board of Directors has declared a base quarterly dividend of $0.75 per share in aggregate for the second quarter of fiscal 2027, paid in three monthly dividends as follows:Month Amount per Share Record Date Payment DateJune 2026 $0.25 July 6, 2026 July 23, 2026July 2026 $0.25 August 5, 2026 August 25, 2026August 2026 $0.25 September 3, 2026 September 23, 2026       “Our board of directors approved an unchanged quarterly dividend of $0.75 per share for the second quarter of fiscal 2027, paid in monthly increments of $0.25 per share. Annualizing this dividend rate implies a 13.4% dividend yield based on Saratoga’s recent stock price of...

Advanced Sensor Test TrackAdvanced Sensor Test TrackMulti Dyno Test CellMulti Dyno Test CellAutostore Automated WarehouseAutostore Automated WarehouseDynamic SimulatorDynamic SimulatorCNH accelerates product development and parts delivery with €21M investment in advanced simulation and automated logisticsCNH invests €21M in advanced simulation and automated logistics in Modena, Italy, to accelerate product development and parts delivery across Europe New virtual simulation ecosystem reduces development time by over 30% by identifying design issues earlier and optimizing testing processes Automated AutoStoreTM warehouse enables 24-hour parts availability for 1,200+ dealers, improving speed, efficiency, and sustainabilityModena, June 11, 2026 CNH (NYSE: CNH), a global leader in agricultural and...

Structured Market Entry Includes Initial Purchase Order and Pathway to Five-Year Commercial Partnership VANCOUVER, BC, June 11, 2026 (GLOBE NEWSWIRE) — VVT Med Inc. (TSXV: VVTM) (“VVT Med” or the “Company”), a developer of minimally invasive, non-thermal, non-tumescent (“NT-NT”) solutions for venous disease, today announced its entry into the Dominican Republic market through a Trial Distribution and Evaluation Agreement (the “Agreement”) with Antilles Medical (“Antilles”), a local distributor with established clinical and commercial infrastructure in the region. Under the Agreement, Antilles has been appointed as VVT Med’s exclusive distributor for ScleroSafe™ in the Dominican Republic for an initial evaluation period. The arrangement includes an initial...

Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Southlake, TX, June 11, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced the grant by the European Patent Office (EPO) of European Patent No. EP4252651, titled “Electrocardiogram-Based Assessment of Diastolic Function.” The patent covers machine-learning models and methods for computing quantitative estimates of echocardiogram parameters indicative of diastolic function using ECG data and patient demographic parameters. “Securing European patent protection for ECG-based...

Incoming Chief Executive Officer Brings Two Decades of Defense Leadership, Most Recently at Israeli Loitering-Munitions Innovator SpearUAV, and Previously at Rafael Advanced Defense Systems, One of Israel’s Leading Defense Companies Current CEO and President Yossef Balucka to Continue as President, Focusing on Advancing Duke’s Commercial Business and Customer Relationships FT. LAUDERDALE, FL, June 11, 2026 (GLOBE NEWSWIRE) — Duke Robotics Corp. (Nasdaq: DUKR; DUKRW) (“Duke Robotics” or the “Company”), a leader in advanced robotics and drone-based solutions for civilian and defense markets, today announced the appointment of Yiftach Kleinman as Chief Executive Officer, with such appointment becoming effective upon the commencement of his employment with the Company, which is expected to occur...

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced today that its Chief Medical Officer (“CMO”) Adrian Quartel, M.D., FFPM, will be stepping down from his position due to personal reasons, effective July 3, 2026. Dr. Quartel will continue to support Zevra in a consulting capacity through December 31, 2026, while the Company conducts a search for its next CMO and ensures a seamless transition. “On behalf of everyone at Zevra, we are grateful for the role Adrian played in advancing our mission and positioning us for success. Over the past several years, he has been a trusted partner, contributing to the FDA approval and commercial launch of MIPLYFFA, advancing...

Brings more than 25 years of experience leading transformation, capital deployment, and growth initiatives across global businessesJohn Fortson, Chief Financial OfficerJohn Fortson, Chief Financial OfficerCHARLOTTE, N.C., June 11, 2026 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies, today announced the appointment of John Fortson as Executive Vice President (EVP) and Chief Financial Officer (CFO), effective July 20. Mr. Fortson joins Dentsply Sirona with more than 25 years of leadership experience in finance, operations, and strategy across both public and private equity-backed companies. He has served for 13 years as either CFO or Chief Executive Officer...

BOCA RATON, FL, June 11, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first U.S. public company with a treasury strategy built around accumulating and compounding Solana (SOL), today announced it will host its May 2026 Business Recap & Ask Me Anything (“AMA”) today, June 11, 2026, at 11:00 AM ET via X Spaces. The event will provide shareholders, analysts, and the broader community with a comprehensive review of DFDV’s progress during May 2026, including updates on treasury operations, capital markets activity, ecosystem partnerships, and broader developments across the Solana ecosystem. Members of the Company’s leadership team will also answer live questions from retail investors and the broader community. Participants can join the live event by visiting DeFi Development Corp.’s official...